A Study of Gilteritinib (ASP2215) Combined With Chemotherapy in Children, Adolescents and Young Adults With FMS-like Tyrosine Kinase 3 (FLT3)/Internal Tandem Duplication (ITD) Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase 1/2 Terminated
9 enrolled 21 charts
UPCC 25406
Phase 1/2 Terminated
4 enrolled
Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 1/2 Terminated
4 enrolled 8 charts
Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement
Phase 1/2 Terminated
6 enrolled 13 charts
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
Phase 1/2 Terminated
17 enrolled 15 charts
A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors
Phase 1/2 Terminated
38 enrolled 34 charts
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)
Phase 1/2 Terminated
70 enrolled
Study of Fosciclopirox in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1/2 Terminated
18 enrolled
Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia
Phase 1/2 Terminated
16 enrolled 13 charts
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Phase 1/2 Terminated
24 enrolled 14 charts
Dasatinib, Cytarabine, and Idarubicin in Treating Patients With High-Risk Acute Myeloid Leukemia
Phase 1/2 Terminated
20 enrolled 9 charts
An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase 1/2 Terminated
70 enrolled 36 charts
AML-02: Omacetaxine With Standard-of-Care Induction With Cytarabine & Idarubicin in Newly-Diagnosed AML Patients
Phase 1/2 Terminated
22 enrolled 17 charts
ABT-751 With Chemotherapy for Relapsed Pediatric ALL
Phase 1/2 Terminated
9 enrolled 12 charts
PrE0901
Phase 1/2 Terminated
15 enrolled 5 charts
ENTO in AML
Phase 1/2 Terminated
148 enrolled 26 charts
Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic (MD) Syndrome With Laromustine and Infusional Cytarabine
Phase 1/2 Terminated
25 enrolled
Clinical Study of Plitidepsin (Aplidin®) in Combination With Cytarabine in Patients With Relapsed/Refractory Leukemia
Phase 1/2 Terminated
3 enrolled 6 charts
Ifosfamide, Carboplatin, Etoposide, and SGN-30 in Treating Young Patients With Recurrent Anaplastic Large Cell Lymphoma
Phase 1/2 Terminated
5 enrolled 9 charts
R²-DHAP
Phase 1/2 Terminated
34 enrolled
Dose Escalation Phase I/II Study of Lovastatin With High-Dose Cytarabine for Refractory or Relapsed AML
Phase 1/2 Terminated
23 enrolled 8 charts
Cytosine Arabinoside and Mitoxantrone for Patients With Juvenile Myelomonocytic Leukemia Receiving Repeat Stem Cell Transplantation
Phase 1/2 Terminated
1 enrolled 7 charts
Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
Phase 1/2 Terminated
27 enrolled 5 charts
Safety and Efficacy of Imatinib in Combination With High Dose Chemotherapy for Acute Phase Chronic Myelogenous Patients
Phase 1/2 Terminated
30 enrolled